Physician profile
Danielle Marche Perry
NPI 1659140432
$2,174.67
in general payments reported to CMS, 2019-2025
25 companies · $1,152 in 2025
The $1,152 reported for 2025 was more than what 89% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,023 · 2025: $1,152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,174.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $322.33 | 2024-2025 | |
| Lilly USA, LLC | $249.81 | 2024-2025 | Mounjaro, Jardiance, Zepbound |
| Lundbeck LLC | $218.56 | 2024-2025 | Rexulti |
| Novo Nordisk INC | $185.68 | 2024-2025 | Rybelsus, Ozempic |
| Corcept Therapeutics | $164.16 | 2024-2025 | Korlym |
| Astellas Pharma US INC | $146.36 | 2024-2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $142.36 | 2024-2025 | Airsupra, Breztri |
| Phathom Pharmaceuticals, INC. | $111.53 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.02 | 2024-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $99.55 | 2024-2025 | |
| Amgen INC. | $53.98 | 2025 | Repatha, Otezla |
| Philips North America LLC | $48.40 | 2024 | (Ck4) Mcot, (Ck7) Extended Holter |
| Bayer Healthcare Pharmaceuticals INC. | $38.73 | 2025 | |
| Alkermes, INC. | $37.84 | 2025 | Lybalvi |
| Exact Sciences Corporation | $35.08 | 2025 | Cologuard Collection Kit |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $31.91 | 2024 | |
| Eisai INC. | $29.28 | 2024 | |
| Organogenesis INC. | $25.14 | 2025 | Affinity |
| Takeda Pharmaceuticals U.S.A., INC. | $21.36 | 2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.21 | 2024 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.57 | 2025 | Xifaxan |
| Ibsa Pharma INC. | $18.01 | 2025 | Tirosint, Flector, Licart |
| Dexcom, INC. | $17.97 | 2024 | Dexcom G6 Transmitter |
| Inspire Medical Systems, INC. | $16.95 | 2024 | Inspire |
| Esperion Therapeutics, INC. | $15.88 | 2024 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Perry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.